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Background: Understanding the heterogeneous genotypes and phenotypes of prostate cancer is fundamental to
improving the waywe treat this disease. As yet, there are no validated descriptions of prostate cancer subgroups
derived from integrated genomics linked with clinical outcome.
Methods: In a study of 482 tumour, benign and germline samples from 259 men with primary prostate cancer,
we used integrative analysis of copy number alterations (CNA) and array transcriptomics to identify genomic loci
that affect expression levels of mRNA in an expression quantitative trait loci (eQTL) approach, to stratify patients
into subgroups that we then associated with future clinical behaviour, and compared with either CNA or tran-
scriptomics alone.
Findings:We identiﬁed ﬁve separate patient subgroups with distinct genomic alterations and expression proﬁles
based on 100 discriminating genes in our separate discovery and validation sets of 125 and 103 men. These sub-
groupswere able to consistently predict biochemical relapse (p=0.0017 andp=0.016 respectively) andwere fur-
ther validated in a third cohort with long-term follow-up (p= 0.027). We show the relative contributions of gene
expression and copy number data on phenotype, and demonstrate the improved power gained from integrative
analyses. We conﬁrm alterations in six genes previously associated with prostate cancer (MAP3K7,MELK, RCBTB2,
ELAC2, TPD52, ZBTB4), and also identify 94 genes not previously linked to prostate cancer progression that would
not have been detected using either transcript or copy number data alone.We conﬁrm a number of previously pub-
lishedmolecular changes associatedwith high risk disease, includingMYC ampliﬁcation, andNKX3-1, RB1 and PTEN
deletions, as well as over-expression of PCA3 and AMACR, and loss ofMSMB in tumour tissue. A subset of the 100
genes outperforms established clinical predictors of poor prognosis (PSA, Gleason score), as well as previously pub-
lished gene signatures (p= 0.0001). We further show how our molecular proﬁles can be used for the early detec-
tion of aggressive cases in a clinical setting, and inform treatment decisions.
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Interpretation: For the ﬁrst time in prostate cancer this study demonstrates the importance of integrated genomic
analyses incorporating both benign and tumour tissue data in identifying molecular alterations leading to the gen-
eration of robust gene sets that are predictive of clinical outcome in independent patient cohorts.
Crown Copyright © 2015 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Disease stratiﬁcation based on molecular signatures has aided the
management of other epithelial cancers such as breast cancer (Curtis
et al., 2012). In contrast, prostate cancer treatment decisions are still
based almost exclusively on histological architecture (Gleason score)
(Gleason, 1966; Gleason andMellinger, 1974), prostate-speciﬁc antigen
(PSA) levels (Catalona et al., 1994) and local disease state (TNM, WHO
2009), without attention to molecular characteristics. However, recent
studies show that prostate cancer can be stratiﬁed according to molec-
ular signatures (Glinsky et al., 2004; Varambally et al., 2005; Tomlins
et al., 2007; Irshad et al., 2013; Taylor et al., 2010). Prostate cancer is
the most non-cutaneous common cancer in males in the UK and USA
(www.cancerresearchuk.org and www.cdc.gov) and genetic changes
associated with aggressive disease, when present in early tumours,
herald the onset of early biochemical relapse (Ramos-Montoya et al.,
2014). Early treatment of primary prostate cancer is very effective, but it
is still difﬁcult to identify those patients who are likely to progress and
to treat them appropriately.
Herewe describe the comprehensive, integrated analysis of genomic
and transcriptomic data from 351 tissue and blood samples from 156
British men, including 125 radical prostatectomy (RP) samples, 118
with matched benign tissue; 64 matched germline DNA; 19 castrate-
resistant prostate cancer (CRPC) from channel transurethral resection
of the prostate (chTURP) samples, 13 with matched germ-line DNA,
and 12 independent samples with benign prostatic hyperplasia (BPH).
We identify ﬁve distinct molecular proﬁles for primary prostate cancer
that are predictive of biochemical relapse, based on the integrative anal-
ysis of transcript levels and somatic copy number alterations (CNAs).
These ﬁndings hold when castrate-resistant prostate cancers are
Table 1
Summary of clinical characteristics of discovery (Cambridge) and validation (Stockholm) cohorts.
Cambridge Stockholm
Primary tumour — RP CRPC — chTURP Primary tumour — RP
n = 125 % n = 19 % n = 103 %
Age (years)
Mean 60.9 72.4 63.9
Range 41–73 59–93 54–75
Pre-operative PSA (ng/ml)
b4 3 2% 0 7 7%
4–10 87 70% 3 16% 60 58%
N10 34 27% 16 84% 28 27%
Unknown 1 1% – 8 8%
Gleason Grade (RP)
5 – – 2 2%
6 18 14% – 20 19%
7 (3 + 4) 76 61% 58 56%
7 (4 + 3) 21 17% 1 5%
8 8 6% 2 11% 6 6%
9 2 2% 9 47% 9 9%
10 0 0% 2 11% 1 1%
Neuroendocrine – 1 5% –
Small cell – 1 5% –
Ungraded/unknown – 1 5% 7 7%
Pathology stage
pT2 38 30% – 52 50%
pT3a 76 61% – 28 27%
pT3b 9 7% – 15 15%
pT4 2 2% –
Unknown 6 6%
Follow-up (months)
Mean 37 – 78
Range 2–67 – 2–122
Biochemical relapse 21 17% – 48 47%
% tumour cellularity
Mean 52% 65% tissue selected for ≥70%
Range 20%–90% 20%–95%
Positive surgical margins 30 24% – 44 43%
Extra-capsular extension 87 70% 1 5% 43 42%
Metastases 1 1% 2 11% 4 4%
ERG status⁎
2EDEL 8 6% – –
2ESPLIT 12 10% – –
EDEL 20 16% – –
ESPLIT 17 14% – –
N 64 51% – –
Unknown 4 3% – –
⁎ According to Attard et al. (2008).
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considered, and further replicate in a separate cohort of 206 samples
from 103 Swedish primary prostate cancers with long-term follow-up
(Table 1). We further validate our prognostic molecular proﬁles in a
well-established American cohort (Taylor et al., 2010), the only pub-
lished study of similar size with comparable genomic and clinical data
at the time (Suppl. Table 1). An overview of the data generation is pro-
vided in Table 2.We describe key genetic changes that stratifymen into
different risk groups and suggest possible therapeutic and prognostic
application for these discoveries.
2. Methods
2.1. Patient samples
Ethical approval for the use of Cambridge samples and data collec-
tionwas granted by the local Research Ethics Committee under ProMPT
(Prostate Mechanisms for Progression and Treatment) “Diagnosis, in-
vestigation and treatment of prostate disease” (MREC 01/4/061). The
Cambridge discovery cohort comprised 358 fresh frozen samples from
156men, including 125 primary prostate cancer from radical prostatec-
tomy (RP) with matched benign tissue, 64 matched germline genomic
DNA (gDNA), 19 castrate-resistant prostate cancer (CRPC) from channel
transurethral resection of the prostate (chTURP), 13 with matched
germline gDNA, and 12 independent benign samples from holmium
laser enucleation of the prostate (HoLEP). The Stockholm validation co-
hort comprised 206 samples of 103 primary prostate cancer with
matched germline DNA, as previously described and 99 samples of
mRNA (Liu et al., 2013), and was selected for 50% rate of relapse. Com-
prehensive clinical (diagnostic) data were collected for each cohort, in-
cluding pre-operative and 6-monthly follow-up PSA, TNM staging and
Gleason score (Table 1; Suppl. Table 2). In all cases, biochemical relapse
was deﬁned according to EuropeanGuidelines as a persistent rise above
0.2ng/ml (Mottet et al., 2014) or triggered salvage radiotherapy.
2.2. Histopathology
Cambridge samples were prepared as described (Warren et al.,
2013). Relative proportions of benign, epithelial, stromal and tumour
cells were determined by consultant histopathologist (AW) (Suppl.
Table 2); samples with ≥20% tumour and matched non-tumour cores
(when available) were included (Yuan et al., 2012). Stockholm samples
were similarly assessed (LE), and included with ≥70% tumour content.
2.3. Genomic processing
Cambridge: gDNA and total mRNA were extracted from tissue
samples (Qiagen AllPrep), and gDNA from whole blood (Tepnel). All
DNAs were assayed on Illumina HumanOmni2.5–8 M bead chip arrays;
16 samples were also assayed on Affymetrix SNP6 arrays (Aros,
Denmark). Stockholm gDNA samples were assayed on Affymetrix
SNP6 arrays, as previously described (Liu et al., 2012). All mRNAs
were proﬁled on Illumina HT12 v4 BeadChip arrays.
2.4. Expression data analysis
For each cohort, bead level data were pre-processed to remove
spatial artefacts, log2-transformed and quantile normalized using the
beadarray package (Dunning et al., 2007) in Bioconductor prior to analy-
sis. The ComBAT method (Johnson et al., 2007), as implemented in the
sva Bioconductor package, was used address batch effects in the expres-
sion data. Like othermicroarray technologies, Illumina arrays are known
to harbour a large number of probes that do notmatch their intended ge-
nomic location, or map to genomic locations that are not useful for gene
expression studies (Barbosa-Morais et al., 2010). Furthermore, including
such probes in an analysis can be misleading (Dunning et al., 2010). We
therefore restricted downstream analyses to ‘perfect’ probes only
(Barbosa-Morais et al., 2010), and whenever a gene-centric analysis
was required we chose the probe with the highest Inter-quartile range
(IQR) to represent each gene. Probes (genes)were ranked by IQR values,
and the 100 most variable probes across expression data were selected
for clustering, based on k-meansmethod (see Chalise et al., 2014 for a re-
view on clustering methods), where each observation belongs to the
cluster with the nearest mean that best describes that cluster. A linear
modelling approach was used to estimate the expression of each probe
in the ﬁve subtypes, and the set of matched benign samples. Differential
expression statistics for the comparison of each subtype to benign were
then generated following Bayes' shrinkage of variance (Smyth, 2004).
2.5. Copy number analysis
Data were pre-processed and quality checked using ‘Call Rate QC’
(AROS), gender calls from PennCNV (Wang et al., 2007); sample
pairings were conﬁrmed using BADGER (Lynch et al., 2012). SNP6
datawere analysedwithASCAT (Van Loo et al., 2010), where Cambridge
& Stockholm data were mapped to hg19, and Taylor et al. (2010) data
were mapped to hg18. Discovery cohort samples included all available
tumour and matched benign pairs. Copy number-related ﬁgures are
coloured accordingly with intensity illustrating degree of gain/loss.
CN = 2 is diploid, 0/1 indicates homo- or heterozygous loss; 3/4 indi-
cates hetero- or homozygous gain; Discovery cohort was analysed in
OncoSNP (Yau et al., 2010), using only rank1 & 2 calls (out of ranks1–
5) for CNAor LOHat each genomic location; this captures larger changes
and/or highest conﬁdence. This collapses CN segments to all local genes
with the same CN state; OncoSNP reports a separate segment when it
sees a gene with a different CN state. All loci altered (CN ≠ 2) in at
least 10% of samples were included, so a total of 117 primary RP tumour
Table 2
Number and type of tissue analysed by each platform.
Cambridge discovery Stockholm validation Total
Platform Primary
(RP)
Benign
(RP)
Germline
(RP)
Benign
(HoLEP)
CRPC
(chTURP)
Germline
(chTURP)
Platform Primary
(RP)
Benign
(RP)
OMNI2.5 M (CN) 125 118 64 matched
85 total
4 16 13 SNP6 (CN) 103 103 482
HT12 (mRNA) 115 67 – 12 19 – HT12 (mRNA) 99 – 312
TMA 125 125 N/A 6 12 N/A TMA – – 268
CN & mRNA 115 67 – 4 16 – CN & mRNA 99 – 301
CN & mRNA &TMA 115 67 – 4 12 – CN & mRNA &TMA – – 198
CN= copy number.
RP = radical prostatectomy.
HoLEP = holmium laser enucleation of the prostate.
chTURP = channel transurethral resection of the prostate.
OMNI2.5 M = Illumina OMNI2.5 M Genotype Beadchip.
SNP6 = Affymetrix SNP6 Genotype array.
HT12 = Illumina HT12 Expression Beadchip.
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sampleswere included in this analysis. Stockholm validation cohortwas
analysed in ASCAT (Van Loo et al., 2010), with all calls displayed.
Genome plots were generated using ggbio package in Bioconductor
(Yin et al., 2012). Percentage genomic alteration (PGA) was calculated
by summing thenumber of baseswith CN ≠ b2, and dividing by 3 billion.
Only OncoSNP rank1 calls (highest conﬁdence) were included.
2.6. Integrative clustering & iCluster comparison
See Supplementary Methods.
2.7. Pathway analysis
Gene ontology pathway enrichment was determined using GeneGo
MetaCore (Thomas Reuters) and http://www.pantherdb.org/ using
default settings and FDR p ≤ 0.05. All genes with log2FC ≥ +1 or
log2FC ≤ −1 difference in expression were used in each analysis, to
ensure a meaningful number of targets were included for gene-set
enrichment analyses, to determine whether any particular pathways
or nodes were speciﬁc to different clusters.
2.8. ERG gene status
TMPRRS2-ERG gene fusion status was determined for Cambridge RP
samples using a break-apart FISH assay on purpose-made tissue micro-
arrays as previously described (Clark et al., 2008) from tissue cores ad-
jacent to those included in the genomics study— see below. Categories
usedwere based on thosewith known clinico-pathological associations;
whenmixed signals were identiﬁed, the sample was assigned to the de-
letion or split category with the most signiﬁcant clinical implications,
according to Attard et al. (2008); i.e. according to increasing order of
severity 2 N, N, ESPLIT/2ESPLIT, EDEL/2EDEL.
2.9. Study TMA
Single 3 mm cores from the immediately adjacent slice of each
patient tumour and benign core used for genomic analysis (RNA and
DNA); i.e. if ‘vial 6’ was used for genomic study (based on percentage
tumour cellularity), then a core was punched from the parraﬁn
megablock in the region immediately neighbouring this vial on the
prostate map (see Suppl. Table 2).
3. Results
In previous studies of breast (Curtis et al., 2012) and prostate cancer
(Taylor et al., 2010), it has been suggested that either copy number or
transcriptomic proﬁling alone provides superior clinical prediction.
We therefore considered these data separately, before carrying out an
integrated analysis combining CN datawith associatedmRNA transcript
proﬁles of gene targets in an eQTL approach.
3.1. Copy number proﬁling
The overall genome-wide copy number (CN) proﬁle of the
Cambridge (discovery) cohort is consistent with previous ﬁndings,
with chromosome 8p loss/8q gain evident (Fig. 1). The detection of
known prostate cancer risk CN changes (Williams et al., 2014; Sun
et al., 2007) in our cohort is broadly consistent with other studies
(Suppl. Table 3), with key tumour suppressor NKX3-1 (8p21.2) deleted
in 40% of samples, and RB1 (24%), PTEN (18%), and TP53 (11%) deletions
also easily detected even with very stringent call ranking selection
criteria applied (see Methods). A similar overall proﬁle is evident in
the Stockholm validation data set (Suppl. Fig. 1), despite being assayed
and analysed on different platforms (see Methods). These ﬁndings
also show that well-established molecular changes in prostate cancer
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in this cohort are shown, see also Suppl. Table 3); only those affected in N10% samples are annotated. Novel CN changes identiﬁed in this cohort (N10% samples) also in our 100-gene
set are indicated in black type. MAP3K7 is highlighted in purple as the only previously known CN-altered risk gene included in our 100-gene signature. Data were generated on high-
density Illumina OMNI2.5M arrays and analysed using OncoSNP (Yau et al., 2010); only highly stringent calls are shown (seeMethods). Chromosome ends are delineated by grey, vertical
stripes. Representative genes with large average fold changes (tumours versusmatched benign) are shown by red (up-regulation) and green spots (down-regulation); right-hand y-axis.
With the exception of OLFM4 (19%, chr13q14.3), these do not coincide with CN alterations.
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are detectable even at relatively low percentage tumour core content
(Table 1).
The prostate cancer genome is dominated bywide-spread deletions:
we found986 genes affected by CN loss, compared to 508 geneswith CN
gains; only alterations affecting ≥10% of the cohort were considered. In-
deed, only chromosome 8q harbours frequent gains, involving many
genes across the whole region. Most lie outside 8q24, although ampliﬁ-
cation atMYC (13%)was conﬁrmed. In addition to somatic copy number
alterations (CNA) in NKX3-1, we identiﬁed nineteen additional genes
across chromosome 8p with at least as many alterations (24–37%).
Only genes with CNAs in more than 10% of samples and also relevant
in the subsequent integrative analysis are highlighted (Fig. 1). All
other genes with CN changes in ≥10% of the cohort are listed in Suppl.
Table 4.
We conﬁrmed previously identiﬁed (Taylor et al., 2010; Lalonde
et al., 2014) CNAs in MAP3K7 (15%; chr6q15), and further reﬁned the
original 58Mb signal across the 6q12–6q22 region,with CNAs identiﬁed
in RARS2 (15%) and RNGTT (14%) 1- and 2-Mb upstream of MAP3K7
respectively, as well as CNAs 18.8 Mb downstream, at FIG4 (12%;
chr6q21). In contrast to previous work (Taylor et al., 2010), we did
not see any signiﬁcant correlation with local transcript expression of
RARS2 or RNGTT and deletions atMAP3K7 locus (see below). In addition
to known tumour suppressor RB1 (24%, chr13q14.2), we identiﬁed six
other genes with comparable rates of CN change (18–21%), including
AKAP11, GTF2F2, SETDB2, PHF11, TRIM13, and SUGT1. These span an
8 Mb region, and are therefore probably distinct signals. Although we
conﬁrmed known deletions around CDH1 (8%, chr16q22.1), these
were less frequent than in other studies (Williams et al., 2014; Sun
et al., 2007). However, twice as common in this data set were CN losses
spanning seven additional genes in 16q23.1–16q24.3 (11-16%) not yet
fully characterised, including TCF25, TRAPPC2L, DEF8, WDR59, HSBP1,
COX4I1, and KLHDC4. Conversely, a frequently deleted region on chr5q
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Fig. 3. Copy number and expression levels for 100 clustering genes in each integrated cluster. Mean mRNA expression levels are shown as a heatmap for each of the 100 genes used
to differentiate the integrated clusters. Copy number is displayed as the number of men with a gain or loss in copies of that gene in that cluster. Chromosome location is also given
(see Fig. 2). Scaling as shown.
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near CHD1/APC (Sun et al., 2007) was not that common in our dataset
(38% vs 7%; Suppl. Table 4).
To determine the value of using CNdata alone to stratify patients,we
clustered primary tumours using all loci altered (see Methods), and
identiﬁed ﬁve patient groups with distinct genomic proﬁles (Suppl.
Fig. 2A). Despite this, clustering on the basis of CN proﬁling alone was
not signiﬁcant in a survival analysis (logrank p = 0.063; Suppl.
Fig. 2B), where time to biochemical relapse (BCR) was used as the pri-
mary outcome (see Methods). This is in contrast to previous ﬁndings
that suggested CN state alone can be a prognostic indicator (Taylor
et al., 2010; Lalonde et al., 2014).
3.2. mRNA transcript proﬁling
High levels of variability in gene expression between tumours have
recently been shown to be more useful in identifying prostate, breast,
colorectal and lung cancer risk genes (Gorlov et al., 2014) than
traditional tumour versus normal tissue differential expression
approaches, where genuine genes driving aggressive behaviour can be
obscured by more abundant but less biologically relevant effects. Fur-
thermore, such inter-tumour variability in gene expression has been
shown to have strong association with clinically useful features
(Gorlov et al., 2012), such as Gleason score (prostate cancer) and tu-
mour histology (lung cancer). To consider only the most informative
genes, we applied k-means clustering to the top 100 mRNA transcript
probes with the highest levels of inter-tumour variability in primary
prostate cancer tissues. This partitioned the cohort into ﬁve patient
groups with distinct transcript proﬁles (Suppl. Fig. 3A; see Methods).
Although this analysis identiﬁed known prostate cancer risk genes
AMACR, PCA3, GDF15 and MSMB, as well as several possible candidate
genes showing high levels of inter-tumour variability (Suppl. Fig. 3A &
Suppl. Table 5), survival analysis showed that transcript-only clustering
was not predictive of prognosis (logrank p = 0.11, Suppl. Fig. 3B). In
fact, this approach was only informative on inclusion of a small group
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Fig. 4. Integrative subgroups have distinct clinical outcomes and are powerful predictors of relapse. A. Kaplan–Meier plot of relapse-free survival over 60 months for the ﬁve molecular
subtypes in the Cambridge discovery cohort (p = 0.0017 for the two highest versus two lowest risk groups). For each cluster, the total number of samples is indicated (total relapses
in brackets). B. Kaplan–Meier plot of relapse-free survival over 96 months in the Stockholm validation cohort (p = 0.016). Further validation was undertaken in a third dataset
(Taylor et al. (2010); Suppl. Fig. 9). C. Distribution of Gleason grade across subtypes (Cambridge discovery cohort); no Gleason score predominates in any one subtype (Kruskal–Wallis
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(n = 6) of outliers which dominated the test statistic (Suppl. Fig. 3C).
For completeness, we also assessed sample clustering based on clinical
risk factors. As expected, surgical Gleason score was a reliable prognos-
tic indicator (logrank p=5× 10−6; Suppl. Fig. 4A), but no other clinical
covariate tested was statistically signiﬁcant (Suppl. Fig. 4B–F). To check
our approach, we also considered a traditional fold-change analysis,
which conﬁrmed, for example, PCA3, GDF15 and MSMB transcript ex-
pression as disrupted but unrelated to underlying changes at the DNA
level (Fig. 1). We also identiﬁed putative tumour suppressor OLFM4 to
have the highest fold-change in expression (all tumour versus matched
benign), an effect recently ascribed to CN loss (19% in our data set) and
linked to prostate cancer progression (Li et al., 2013).
3.3. Integrative analysis identiﬁes distinct patient subtypes with
characteristic molecular proﬁles
Previous studies have shown that most heritable gene expression
traits are predominantly controlled by cis-acting proximal loci
(b1Mb), and that these signals are consistentlymore abundant and sta-
ble than more distal trans effects (Curtis et al., 2012). For an integrative
analysis – combining copy number and gene expression data – we
selected features displaying linear correlations between CN state and
local transcript expression levels, to identify genome-wide expression
quantitative trait loci (eQTL) in the discovery data set (see Methods).
These eQTL features were used in a joint latent variable framework
for integrative analysis (iClusterPlus (Mo et al., 2013); see Methods),
which identiﬁed ﬁve distinct molecular subtypes (iCluster1–5) in the
Cambridge cohortwith characteristic copynumber and gene expression
proﬁles (Fig. 2). These were driven by a core set of 100 genes that had
both CN and mRNA level changes (Suppl. Table 6). We conﬁrmed this
by comparing the results for alternative numbers of clusters (2–11)
and features (100 to 1000) (see Suppl. Fig. 5A–C; Suppl. methods).
These ﬁve clusters (k= 4; 100 features) describe 60% of the total ob-
served variance (Suppl. Fig. 5A). These same 100 gene features were
used to train a classiﬁer, and partition the Stockholm data set into ﬁve
patient subtypes with characteristic proﬁles (Suppl. Fig. 6), similar to
those described in the discovery cohort.
We assessed transcript and copy number levels for these 100 classi-
fying genes for both the discovery and validation cohorts (Fig. 3). There
was clear consistency of expression and copy number aberrations in
trained clusters with the exception of subsets of genes in iCluster 2
and 5, which displayed marked copy number ampliﬁcation in the
Stockholm cohort. There was consistent copy number loss and down-
regulation of expression of genes on chromosome 8 (e.g. MTMR9,
LSM1 and ER1) in two particular subgroups iCluster 1 and 3, while
iCluster 3 was characterised uniquely by copy number gain and upreg-
ulation of neighbouring genes on chromosome 8 (e.g. RIPK2, SPIDR and
IMPA1). By contrast, iCluster 4 had consistent copy number loss and
downregulation of genes on chromosome 13 (e.g. TRIM13, PHF11 and
SUGT1).
Finally, we considered the sample groups identiﬁed by our integra-
tive analysis (Fig. 4A) as ‘true’ clusters with clinical relevance, and com-
pared these ‘true’ clusters to the sample groupings suggested by either
copy number (Suppl. Fig. 2) or gene expression data alone (Suppl.
Fig. 3). We used two different approaches to determine the similarity
of the alternative clustering methods to the ‘true’ clusters. Based on
both the Adjusted Rand Index (ARI) (Hubert and Arabie, 1985) and the
Variation of Information Index (VII) (Meilă, 2007), sample clustering
based on CN-data is more similar to integrative (‘true’) clustering than
is expression-based clustering (Suppl. Table 7; Suppl. methods).
3.4. The ﬁve subgroups are prognostic in multiple clinical cohorts
Survival analysis showed that these patient subgroups, driven by
the 100-gene set, were predictive of outcome in the Cambridge cohort,
and clearly distinguished patient groups with better (e.g. blue line;
iCluster2) and worse prognosis (e.g. red line; iCluster1), based on
BCR-survival data over 60 months (logrank p = 0 · 015; Fig. 4A).
Clinical characteristics of the primary tumours in each cluster are
given in Suppl. Fig. 7, which also shows the distribution of CRPC samples
across the clusters. Tumours with poor prognosis Gleason scores
(≥4 + 3) are distributed across clusters (Fig. 4C; Kruskal–Wallis p =
0.6194), showing that the molecular subtypes identiﬁed are not driven
solely by tumour grade. Except for explicable differences in BCR be-
tween clusters (chi-squared p = 0.0462), and also extra-capsular ex-
tension (chi-squared p = 0.029), these molecular subgroups are not
obviously due to other known prostate cancer risk factors (Suppl.
Fig. 8), suggesting that these molecular proﬁles describe additional bio-
logical detail that has important prognostic signiﬁcance.
These ﬁve patient clusters were similarly prognostic in our second,
novel Stockholm validation cohort (logrank p = 0.048, Fig. 4B), where
the extended BCR data (100 months) allowed us to further assess the
reliability of the sub-groups in predicting relapse. For example, we
found that 56% and 78% of men in iClusters1 and 3 respectively,
progressed to relapse disease. Finally, this 100-gene set also replicated
in a third, published cohort with similar long-term follow-up (Taylor
et al., 2010) (logrank p = 0.027) (Suppl. Fig. 9A; see Suppl. Table 8 &
Suppl. Fig. 9B for clinical features of this cohort). Our method assigned
109 patients to clusters with good or poor outcome, similar to the anal-
yses in our discovery (n= 125) and replication (n= 103) cohorts. This
further demonstrates our gene set's utility and reproducibility in consis-
tently identifying patient groups.
Finally, we determined Cox proportional hazard ratios (PHR) for
Gleason score (≥4 + 3 = 7 vs ≤3 + 4 = 7), PSA levels (high N10ng/ml
vs low b10ng/ml), presence of extra-capsular extension (ECE), and
positive surgical margins (PSM). We also compared each subgroup to
the best outcome cluster (iCluster4) (Fig. 4D), in a combined analysis
of the Cambridge and Stockholm data sets, to ensure sufﬁcient events
for robust statistical testing (Peduzzi et al., 1995). We found that
iClusters1 and 3 identiﬁed men with the highest risk of relapse more ef-
fectively than either elevated Gleason score (≥4 + 3), high PSA, ECE or
PSM.
3.5. Genomic features of the molecular subtypes identiﬁed
In both the Cambridge and Stockholm data sets, the two groupswith
the best outcomes (iClusters2 and 4) were notable for having relatively
few changes in copy number or expression. Conversely, the two groups
with poor outcome (iClusters1 & 3) showed signiﬁcant genomic insta-
bility, with large regions of CN gain and loss evident, as well as many
more differentially expressed genes (log2FC b−2 or N+2) (Fig. 2) in
both cohorts. All cluster-speciﬁc differentially expressed genes (DEGs)
with log2FC N1.5 or b−1.5 are given in Suppl. Table 9. Notably, dramatic
CN changes were not always associated with changes in gene expres-
sion level. For example, the marked CN losses and gains at chr8p and
8q respectively, particular to poor-prognosis iCluster3 subtype, were
not correlated with marked changes in the expression levels of local
genes. Conversely, chromosome 19q harbours multiple genes that
were consistently over-expressed in all clusters, but not obviously asso-
ciated with CN gains. These include KLK12 (log2FC 3.2 iCluster3; Fig. 2)
and HPN (log2FC 1.6–2.2), which have both been linked with prostate
cancer aggressiveness (Lose et al., 2013; Holt et al., 2010). Distal gene
FLJ22184 at chr19p encodes a conserved calcium-channel protein most
highly expressed in iCluster4 (log2FC 1.7), but is as yet largely
uncharacterised.
The previously reported eQTL at tumour suppressor gene OLFM4 (Li
et al., 2013) (chr13q) showed no change in CN or associated expression
level in iCluster2. However, a clear deletion at OLFM4 correlated with a
marked reduction in transcript levels in iCluster3 (log2FC 2.6) and, to a
lesser extent, in iClusters1 and 4 (log2FC 1.9 and 1.7, respectively).
Genes typically associated with prostate cancer are evident: PCA3 and
GDF15 levels are elevated, and TP63 andMSMB levels are reduced across
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all tumour subgroups, and are not subtype-speciﬁc. However, AMACR
shows marked over-expression only in the poor outcome iClusters1, 3
and 5 (Fig. 2; Suppl. Table 9). Basal stem cell marker cytokeratin 15
(KRT15; chr17q) was also notably down-regulated in these clusters,
and may therefore be a useful biomarker of more aggressive disease,
as has previously been reported in high-grade squamous epithelial neo-
plasms (Khanom et al., 2012). In addition, TRPM4 (chr19q), encoding a
calcium-activated ion channel, is up-regulated in all clusters except
best-prognosis iCluster2, and was recently identiﬁed as a driver gene
in the progression to androgen-independent prostate cancer (Schinke
et al., 2014), possibly via its role in cell proliferation and β-catenin sig-
nalling (Armisén et al., 2011). Loss of MSMB expression shows the
same pattern – markedly reduced in all but good outcome iCluster2 –
consistent with its reported role in prostate cancer (Grisanzio et al.,
2012). Principal components analysis (PCA) of gene signatures that
may predict early BCR (Ramos-Montoya et al., 2014; Massie et al.,
2011; Sharma et al., 2013; Mendiratta et al., 2009) on the Cambridge
mRNA data set identiﬁed associations between key pathways in pros-
tate cancer and molecular subtype (Suppl. Fig. 10). A summary of
probe expression by iCluster is given (Suppl. Fig. 11). Together, these
data suggest differences in the expression of transcripts associated
with transcription factors such as AR, ERG or HES6 (Lamb et al., 2014)
within certain prostate cancer subtypes, as well as certain changes in
the expression of speciﬁc transcripts such as NKX3-1 upregulation
(iCluster 5), CDH1-up (iCluster 3), cyclin-D1 down (iCluster 2) and
TP53 downregulation (iCluster 3), consistent with previous ﬁndings
(Markert et al., 2011).
Recent reports have also shown that genomic instability itself – as
measured by the percentage of the genome affected (PGA) by copy
number changes – is also highly prognostic of PSA recurrence (Taylor
et al., 2010; Lalonde et al., 2014; Hieronymus et al., 2014). We therefore
determined the PGA for each patient iCluster in both discovery and
validation cohorts (see Methods), and found that genomic instability
differs signiﬁcantly between each genomic subtype in both datasets
(Suppl. Fig. 12): Kruskal–Wallis p = 4.463 e− 11 (Cambridge); p =
0.0009246 (Stockholm). In each case, iCluster3 showed the highest per-
centage of genome affected, in keeping with our observations that this
subgroup has the most genomic ‘activity’ (Fig. 2).
3.6. Gene signature pathway analysis
The 100 gene set includes six protein kinases (MAP3K7, MYLK2,
RIPK2, PTK2B, MELK, ACVR1) and ﬁve transcription factors (TRIM13,
GTF2E2, PHF11, ERCC3, GTF2F2). Gene ontology analysis revealed
pathways relating to RNA and DNA processing, speciﬁcally sequence-
speciﬁc transcription factor and nucleic acid binding, as well as the
phosphorylation of proteins were strongly associated with this set
(http://www.pantherdb.org/ & Zhang et al., 2005) (Suppl. Fig. 13).
We assessedwhether therewere any genes in commonbetween our
gene set and the top 100 genes with the most variable expression
between tumours (presumed therefore to be the most informative in
clustering based on expression (Gorlov et al., 2012, 2014) Suppl Fig. 3,
Suppl. Tables 5 & 6), but found no overlap. Of the 1493 common CNAs
identiﬁed in our discovery cohort (Suppl. Table 4), 49 (3.3%) were in
our gene set (Suppl. Fig. 14A). We found further limited overlap be-
tween our gene set and any other published genes associated with
risk in prostate cancer, based either on recurrent CN changes
(Williams et al., 2014; 1 gene in common, out of 24), or transcript pro-
ﬁling (Gorlov et al., 2014; 5 genes in common, out of 135) (Suppl.
Fig. 14B). As such, our eQTL-based approach has identiﬁed 94 additional
gene targets that would not have been identiﬁed using copy number or
transcript proﬁling data alone.
Within our 100-gene set, onlyMAP3K7 (6q15) is known to harbour
recurrent CNAs in prostate cancer (Suppl. Fig. 13B & Suppl. Table 3).
Deletions in MAP3K7 have recently been associated with early PSA
recurrence, and in tumours that do not contain the TMPRSS2-ERG gene
fusion, a tumour-suppressor role for MAP3K7 has been proposed
(Kluth et al., 2013). Overlapping the 100-gene set with differentially
expressed genes from iCluster4 (best prognosis) and all other sample
subgroups combined (all non-iCluster4 DEGs), identiﬁed two targets
within the 100-gene set with the potential to distinguish subgroup
iCluster4 from any other patient subtype with respect to gene expres-
sion levels (≥2-fold expression change; Suppl. Fig. 14C). These were
CHMP4C (8q21, CNAs in 12%; 2-fold expression change in cluster3), a
chromatin-modifyingprotein thepromoter ofwhich contains transcrip-
tion factor binding sites for multiple cell cycle control genes, and
receptor-interacting protein kinase 2 (RIPK2) (8q21, CNAs in 14%, 2.5-
fold change in cluster3). Ubiquitinated RIPK2 binds with MAP3K7/
TAK1, translocates to the nucleus and activates a transcriptional cascade
involving genes controlling cellular growth, protection against apopto-
sis and inﬂammatory response via NF-κB activation (Hasegawa et al.,
2008).
Our 100-gene set also showed ‘genomic alteration’ (ampliﬁcations,
deletions, missense or truncating mutations, and mRNA and protein
level changes) in 249/257 prostate cancer samples with complete data
at TCGA (the Cancer Genome Atlas; www.cbioportal.org). CHMP7 and
CCAR2were themost frequently genomically altered genes in the signa-
ture, in 47% and 42% of samples, respectively. EIF4G1was also notable in
that it was the only gene altered at the protein level in 14% of TCGA
prostate cancer samples tested, measured by reverse-phase protein
arrays (RPPA), which suggests it may be a useful histological biomarker.
3.7. The gene signature is prognostic
We tested the prognostic usefulness of the 100 CN and expression
features contained within our integrated gene-set on the Stockholm
cohort (Table 1 & Methods). We found that the 100-gene signature
showed signiﬁcant power to separate out a poor prognosis patient
group with quicker time to recurrence (chi-squared 0.017) in this
large validation cohort (Suppl. Fig. 15A, B). We sought to reﬁne this
set further and identiﬁed subsets of approximately 50 genes (including
copy number and expression features) that best deﬁned each of the ﬁve
iCluster groups (see Suppl. methods).We selected themost informative
subset of genes that predicted biochemical relapse to take forward as a
signature (iCluster 4; Suppl. Fig. 16, Suppl. Table 10).
Since there are several cancer gene signatures available, we tested
the performance of our reﬁned signature against other signatures.
First, we compared it against 1000 randomly selected sets of compara-
ble number of genes (Suppl. methods, Suppl. Fig. 17) (Venet et al.,
2011). Our gene signature was in the 98th percentile of performance
(p b 0.001), with only 18 out of 1 000 random 50-gene signatures
doing better in predicting relapse in the Stockholm data set (Fig. 4E,
F). Then we tested howwell previously identiﬁed oncogenic signatures
were able to predict prognosis in our validation set. Initially, we consid-
ered 189 known oncogenic signatures from multiple cancer types in
MSigDB (Subramanian et al., 2005). A number of the known signatures
Table 3
Performance of signatures in predicting relapse in Stockholm validation cohort.
Signature Gene # Log rank p-value
100-gene set 100 0.0330
iCluster1 32 0.0295
iCluster2 44 0.0185
iCluster3 36 0.0263
iCluster4 50 0.0001
iCluster5 45 0.1560
Sharma et al. (2013)29 16 0.1744
Ramos-Montoya et al. (2014)10 222 0.1892
Cuzick et al. (2011)36 31 0.2631
Irshad et al. (2013)8 19 0.8525
Lalonde et al. (2014)13 100 0.4953
OncoType Dx 17 0.7323
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exhibit prognostic power; however our signature outperforms each one
(p b 0.001; Suppl. methods) (Suppl. Fig. 16). Next, we compared our
gene signature to previously published signatures for prostate cancer
(Irshad et al., 2013; Ramos-Montoya et al., 2014; Lalonde et al., 2014;
Sharma et al., 2013; Cuzick et al., 2011) as well as the Oncotype Dx
Prostate Cancer assay (see Suppl. Table 11; Suppl. methods) to deter-
mine if our genes have prognostic power beyond other possible gene
sets. It should be noted that there was limited overlap between the
signatures (Suppl. Fig. 18). Our 100-gene signature outperformed all
other gene sets in identifying patients with early time to biochemical
relapse in the Stockholm cohort (p = 0.0001; Table 3).
4. Discussion
We have demonstrated that the integration of copy number and
transcript proﬁling data provides effective risk stratiﬁcation of men
with localised prostate cancer in two novel, distinct cohorts totalling
259 men.
Previous approaches to partitioning samples have concentrated
mainly on mRNA biomarkers (Suppl. Table 11). We have clearly
shown that combining these two approaches in an eQTL analysis is
more powerful in predicting outcome (Fig. 4), as well as in identifying
new gene targets also likely to be functionally relevant (Suppl.
Table 7). This insight may be particularly helpful to future studies in-
volving large data sets with multiple classes of genomic information,
for example the Cancer Genome Atlas (TCGA) or the International can-
cer Genome Consortium (ICGC) that are relying on ever higher-
resolution next-generation sequencing approaches to stratify patients
and identify disease-speciﬁc driver mutations. In such studies it will
be important to determinewhich genomicmodiﬁcations are redundant
and which are functionally relevant to the disease.
Our prostate cancer gene signature is associated with a distinct set
of processes (nucleic acid processing, TF-binding and phosphorylation
of proteins) compared to others that relate to cell-cycle control
(Ramos-Montoya et al., 2014; Cuzick et al., 2011) or lipid metabolism
(Lalonde et al., 2014). Nonetheless, there appears to be scant overlap
between prostate cancer gene signatures generally (Suppl. Fig. 17),
possibly due to the trend in generating ever smaller gene signatures.
Despite this, our reﬁned 100-gene set seems, in our analysis, to be
more informative than any other published signature to date (Suppl.
Table 12), and as such presents a practically useful, robust tool to help
clinicians distinguish good and poor outcome disease. Furthermore,
we propose that that it may help tackle the confounding effects of
multi-focal heterogeneity highlighted recently in an in-depth whole
genome sequencing study of three patients with prostate cancer
(Cooper et al., 2015).
Three recent studies have addressed the question of heterogeneity
within prostate cancer, identifyingmultiple foci of differing clonal origin
in each case (Cooper et al., 2015; Gundem et al., 2015; Hong et al., 2015)
and suggesting that single tissue samplings of a prostate risks missing
information about the most important tumour clone. We are unable
to address this directly in our study. However, we ensured that our
specimens contained aminimum 20% tumour (range 20–90%), and fur-
ther validated our ﬁndings in a more strictly deﬁned, mature validation
cohort (Stockholm; ≥70% tumour content; mean 78 month follow-up).
The robust replication of our initial ﬁndings suggests that single sam-
pling is adequate when translated to a large enough cohort of patients.
We also had the opportunity to compare matched tumour and benign
samples to germline DNA in order to assess ﬁeld effects (n = 64 triple
matched samples). This will, no doubt, be of interest to the aforemen-
tioned larger studies (TCGA, ICGC) which also depend mainly on single
samples taken from men with prostate cancer. We suspect that addi-
tional information will also be provided by sampling of genomic alter-
ations from the cell-free DNA in the blood, and look forward to future
publications investigating this approach in prostate cancer (see
Murtaza et al. (2013)).
Our data showed that tumours with poor prognosis Gleason
sums (≥7) were distributed across all ﬁve clusters, suggesting that the
molecular subtypes identiﬁed are not solely driven by histology. Other
biomarkers (elevated PSA, TMPRSS2-ERG deletion)were also represented
(Fig. 3C, Suppl. Fig. 8) across the ﬁve patient subtypes. Furthermore, the
most powerful subtype as regards prognosis was patient subtype
iCluster3, associated with the most marked changes at the molecular
level, and predictive of early biochemical relapse. Further analysis of
this subgroup for mutations not detectable by copy number or SNP anal-
ysis could identify additional, prognosticmolecularmarkers. Importantly,
we demonstrate that we can predict disease relapse based on a reﬁned
subgroup of our classifying gene set, and show the superiority of this
signature compared to other available signatures (Table 3). Nonetheless,
we acknowledge the shortcomings of using biochemical relapse as a
surrogate for survival. We anticipate that these prognostic clusters will
be further tested alongside other parameters as more mature cohorts
become available with reliable disease-speciﬁc and overall survival data.
Our ﬁndings are clinically signiﬁcant because they will assist urolo-
gists in recommending different treatment approaches for those men
who are classiﬁed as being in low, intermediate or high risk categories
according to conventional clinical criteria. To this end, we present the
case of a man within iCluster3 subgroup who had low/intermediate
risk disease on clinical assessment (Gleason 3 + 4, PSA b 10, T
stage b T2c) but who relapsed early (Suppl. material). We propose
that in future, men will be assigned membership to molecular groups
such as this, and that this proﬁling will greatly assist their clinical
management. Molecular signatures associated with the most
aggressive disease will provide a rationale for early adjuvant treatment
immediately after prostatectomy, or indeed after initial biopsy when
such technologies can be applied to an 18 mm core biopsy. Further
functional analyses of the gene targets presented here will also help us
to better understand the biological consequences of tumour-associated
molecular alteration. As such, we present a triple-matched resource of
prostate cancer copy number and expression proﬁling data, with
matched benign tissue and blood, as well as a fully annotated TMA as
an invaluable tool for further translational research into the mutational
landscapes of primary and castrate-resistant prostate cancers.
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